Empowered Patient Podcast

Dr. Eliseo Salinas, head of Research and Development at Delix Therapeutics, is focused on developing drugs to treat central nervous system disorders by addressing synaptic density.  Applying knowledge about psychoplastogens and neuroplastogens, Delix strives to increase connections between neurons in treating depression more quickly and effectively than using antidepressants.  Eliseo explains, "The term psychoplastogen was coined only a few years ago when it was realized that certain substances, like ketamine or psychedelics like psilocybin, produce those increases in synaptic density in hours, not weeks. So, those were termed psychoplastogens. More recently, it is believed that the psychedelics or psychotomimetic effects of those psychoplastogens might not be necessary for the therapeutic benefit." "Neuroplastogens are those compounds that produce an acute increase in synaptic density in hours without producing those psychotomimetics or hallucinatory effects that the typical psychedelics produce." "When y